2016 Press Releases

    Webcast ImageWebcast
    Blueprint Medicines Conference Call, EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (Replay)
    12/01/16 at 12:30 p.m. ET
    Blueprint Medicines Conference Call, EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    Thursday, December 1, 2016 12:30 p.m. ET  
    Webcast PresentationHelp Help
    Click here for webcast
    Add to CalendarHelp Help
    Add to Calendar Click here to add this event to your calendar
    Webcast ImageWebcast
    Blueprint Medicines Conference Call, ASH Annual Meeting & Exposition (Replay)
    12/05/16 at 8:00 a.m. ET
    Blueprint Medicines Conference Call, ASH Annual Meeting & Exposition
    Monday, December 5, 2016 8:00 a.m. ET  
    Webcast PresentationHelp Help
    Click here for webcast
    Add to CalendarHelp Help
    Add to Calendar Click here to add this event to your calendar
    2016 | 2015 | 2014 | 2013 | 2012
    December 07, 2016
    Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
    December 06, 2016
    Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
    December 04, 2016
    Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis
    November 30, 2016
    Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors
    November 28, 2016
    Blueprint Medicines Announces Proof-of-Concept Data from Global Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma
    November 15, 2016
    Blueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trials for BLU-285 and BLU-554 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    November 14, 2016
    Blueprint Medicines Announces Appointment of Marion Dorsch, Ph.D. as Chief Scientific Officer and the Transition of Christoph Lengauer, Ph.D., MBA, to a Newly Created Executive Vice President Role
    November 10, 2016
    Blueprint Medicines Reports Third Quarter 2016 Financial Results
    November 03, 2016
    Blueprint Medicines to Report Third Quarter 2016 Financial Results on Thursday, November 10, 2016
    November 03, 2016
    Blueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trial for BLU-285 in Advanced Systemic Mastocytosis at 2016 ASH Annual Meeting
    October 28, 2016
    Blueprint Medicines to Present Preclinical Data and Provide Enrollment Updates for Phase 1 Clinical Trial for BLU-285 in Advanced Systemic Mastocytosis at ECNM Annual Meeting 2016
    September 09, 2016
    Blueprint Medicines Announces New Drug Discovery Program Targeting PRKACA Kinase Fusions for the Treatment of Fibrolamellar Carcinoma at 10th International Liver Cancer Association (ILCA) Annual Conference
    September 07, 2016
    Blueprint Medicines to Present at Morgan Stanley Global Healthcare Conference
    September 06, 2016
    Blueprint Medicines Announces Appointment of Tracey McCain as Chief Legal Officer and Executive Vice President
    August 09, 2016
    Blueprint Medicines Reports Second Quarter 2016 Financial Results
    August 03, 2016
    Blueprint Medicines to Present at Upcoming Investor Conferences in August
    August 02, 2016
    Blueprint Medicines to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016
    June 01, 2016
    Blueprint Medicines to Present at Upcoming Investor Conferences in June
    May 10, 2016
    Blueprint Medicines Reports First Quarter 2016 Financial Results
    May 03, 2016
    Blueprint Medicines to Report First Quarter 2016 Financial Results on Tuesday, May 10, 2016
    April 15, 2016
    Blueprint Medicines Appoints Lynn Seely, M.D. to Board of Directors
    April 05, 2016
    Blueprint Medicines to Present at 15th Annual Needham Healthcare Conference
    March 17, 2016
    Blueprint Medicines to Present Preclinical Data on RET Inhibitors in an Oral Presentation at American Association for Cancer Research Annual Meeting
    March 15, 2016
    Blueprint Medicines Announces Worldwide Collaboration to Accelerate and Expand its Development of Novel Medicines in the Field of Cancer Immunotherapy
    March 11, 2016
    Blueprint Medicines Reports Fourth Quarter and Full Year 2015 Financial Results
    March 02, 2016
    Blueprint Medicines to Present at Cowen and Company 36th Annual Health Care Conference
    February 16, 2016
    Blueprint Medicines to Present at RBC Capital Markets 2016 Global Healthcare Conference
    February 04, 2016
    Blueprint Medicines Appoints Lonnel Coats to Board of Directors
    January 05, 2016
    Blueprint Medicines Strengthens Executive Leadership Team


    Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | Financial Tear Sheet